Wall Street Analysts Think Design Therapeutics Could Surge .72 percent Read This Before Placing a Bet
DSGN Stock | USD 5.89 0.00 0.00% |
About 52% of Design Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Design Therapeutics suggests that some traders are interested. Design Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Design Therapeutics. Many technical investors use Design Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Design |
The consensus price target hints at a .7 percent upside potential for Design Therapeutics . While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read at zacks.com
Design Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Design Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Design Therapeutics Fundamental Analysis
We analyze Design Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Design Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Design Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Design Therapeutics is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Design Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Design Therapeutics stock to make a market-neutral strategy. Peer analysis of Design Therapeutics could also be used in its relative valuation, which is a method of valuing Design Therapeutics by comparing valuation metrics with similar companies.
Peers
Design Therapeutics Related Equities
HOWL | Werewolf Therapeutics | 6.76 | ||||
ADCT | ADC Therapeutics | 6.50 | ||||
CCCC | C4 Therapeutics | 4.37 | ||||
IKNA | Ikena Oncology | 2.58 | ||||
ACHL | Achilles Therapeutics | 1.03 | ||||
ERAS | Erasca | 0.41 | ||||
CGEM | Cullinan Oncology | 0.37 | ||||
ALVR | Allovir | 2.17 | ||||
STOK | Stoke Therapeutics | 3.24 | ||||
IMCR | Immunocore Holdings | 3.88 | ||||
AADI | Aadi Bioscience | 4.18 | ||||
ALXO | Alx Oncology | 8.70 | ||||
GLUE | Monte Rosa | 14.47 |
Check out Design Therapeutics Hype Analysis, Design Therapeutics Correlation and Design Therapeutics Performance. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Design Therapeutics. If investors know Design will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Design Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.85) | Revenue Per Share 0.001 | Return On Assets (0.14) | Return On Equity (0.18) |
The market value of Design Therapeutics is measured differently than its book value, which is the value of Design that is recorded on the company's balance sheet. Investors also form their own opinion of Design Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Design Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Design Therapeutics' market value can be influenced by many factors that don't directly affect Design Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Design Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Design Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Design Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.